Our current findings of the enhancement of DR5 activation-induced apoptosis by b-AP15 warrant further investigation of b-AP15 in combination with TRAIL or DR5 agonistic antibody as an effective cancer therapeutic regimen in vivo and in the clinic, and underscore the clinical translational significance of this approach. This evidence concerns the gene TNFRSF10B and cancer.